The Convalescent plasma (ConvP) and COVig PK/PD study: a study into the usefulness of treatment with antibodies from plasma to treat or prevent the coronavirus (SARS-CoV-2)

In the ConvP/COVIg PK/PD study we have test subjects who do not produce antibodies themselves against the coronavirus treated with convalescent plasma or hyperimmune globulins (COVig). Previously, there were no studies that investigated how much plasma or COVig should be given be used to ensure that a patient receives sufficient amounts in the weeks or months after administration has antibodies in his/her blood. In this study, blood was taken at fixed times after administration of the plasma or COVig and investigated how many antibodies against the coronavirus were present and for how long. On base From these measurements we built a model that, after administration of plasma or COVig, the can predict the concentration of antibodies in the blood. The study showed that the plasma used in the first year of the COVID19 pandemic cured patients were taken from too few antibodies compared to people without antibodies long-term protection. The developed model can provide a method for the design of future studies to the preventive or therapeutic use of these agents can be used (e.g. against other viruses).